Search
Bentiromide
go.drugbank.com/drugs/DB00522ApprovedWithdrawnBentiromide is a dipeptide that is used in the bentiromide test, which is a screening test for evaluating pancreatic exocrine function and monitoring the adequacy of supplemental pancreatic therapy. … It is typically administered orally. Cases of headache and gastrointestinal disturbances have been reported with the use of bentiromide. Bentiromide is currently not available in the U.S. or Canada.
Categories: Compounds used in a research, industrial, or household settingCatumaxomab
go.drugbank.com/drugs/DB06607ApprovedWithdrawnCatumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells. … Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites [L1122].
Deuruxolitinib
go.drugbank.com/drugs/DB18847ApprovedInvestigational[L51083] Alopecia areata is an autoimmune condition that attacks the hair follicles and leads to unpredictable hair loss in the scalp and other areas of the body. … Deuruxolitinib is a deuterated form of [ruxolitinib] that selectively inhibits Janus kinases (JAK) JAK1 and JAK2.
Synonyms: (3r)-3-(2,2,3,3,4,4,5,5-d8)cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)propanenitrile, 1h-pyrazole-1-propanenitrile, .beta.-(cyclopentyl-2,2,3,3,4,4,5,5-d8)-4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-, (.beta.r)-Categories: MATE 2 Inhibitors, P-glycoprotein substratesMethysergide
go.drugbank.com/drugs/DB00247ApprovedWithdrawnMethysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the carcinoid syndrome. … An ergot derivative that is a congener of lysergic acid diethylamide.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: (+)-N-(1-(Hydroxymethyl)propyl)-1-methyl-D-lysergamide, 1-Methyl-dextro-lysergic acid (+)-1-hydroxy-2-butylamideGaradacimab
go.drugbank.com/drugs/DB15629Approved[L53303,L53283] It is the first inhibitor of factor XIIa to receive market approval.[L53303] … [A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age.
Cysteamine
go.drugbank.com/drugs/DB00847ApprovedInvestigationalCystinosis is a rare disease caused by mutations in the CTNS gene that encodes for cystinosin, a protein responsible for transporting cystine out of the cell lysosome. … A defect in cystinosin function is followed by cystine accumulation throughout the body, especially the eyes and kidneys.
Synonyms: 2-amino-1-ethanethiol, β-MEAProducts: CYSTAGON ® 150 MG, CYSTAGON ® 50 MG CAPSULASFremanezumab
go.drugbank.com/drugs/DB14041ApprovedInvestigationalFremanezumab is a humanized monoclonal antibody targeted against human calcitonin gene-related peptide (CGRP) for the prevention of migraine headaches. … [L11779] Along with other recently approved anti-CGRP therapies such as [galcanezumab], [erenumab], and the oral CGRP antagonist [ubrogepant], fremanezumab represents an important step forward in the treatment
Products: AJOVY 225 MG/1,5 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 3 ADET, AJOVY 225 MG/1,5 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETAlbiglutide
go.drugbank.com/drugs/DB09043ApprovedInvestigationalWithdrawnIt is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA. … Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline).
Categories: Glucagon-like peptide-1 (GLP-1) analogues, GLP-1 AgonistsLevallorphan
go.drugbank.com/drugs/DB00504ApprovedIt should be used cautiously; levallorphan reverses severe opioid-induced respiratory depression but may exacerbate respiratory depression such as that induced by alcohol or other non-opioid central depressants … (From Martindale, The Extra Pharmacopoeia, 30th ed, p683)
Categories: Heterocyclic Compounds with 4 or More RingsSelinexor
go.drugbank.com/drugs/DB11942ApprovedInvestigationalSelinexor, in combination with [bortezomib] and [dexamethasone], is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells. … [L7123] Selinexor was also granted accelerated approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have gone through at least 2 lines of
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: Nexpovio 20 mg Film Kaplı Tablet, 8 TABLET